about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Why not? Sarep­ta’s third Duchenne MD drug sails to ac­cel­er­at­ed ap­proval

5 years ago
Pharma
FDA+

In search of 'house­hold health­care brands of the fu­ture,' Fore­site Cap­i­tal rais­es $969M to sa­ti­ate a tech-heavy ...

5 years ago
Financing

Biden is look­ing be­yond Wood­cock or Sharf­stein for FDA com­mis­sion­er — re­port

5 years ago
People
FDA+

Six years sep­a­rat­ed from a ra­bies vac­cine scan­dal, Chi­na’s Yisheng­Bio grabs $130M to go big in in­fec­tious dis­eases, ...

5 years ago
Financing
China

The mR­NA era is here. MPM be­lieves the fu­ture be­longs to oR­NA — and Big Phar­ma wants a seat at the ta­ble

5 years ago
Startups
Cell/Gene Tx

Covid-19 man­u­fac­tur­ing roundup: As­traZeneca strug­gling to make planned vac­cine de­liv­er­ies to EU; J&J out­lines plans ...

5 years ago
Manufacturing

UCB builds on re­la­tion­ship with Mi­crosoft with new AI deal; Sanofi part­ners with Ger­man AAV vec­tor biotech

5 years ago
News Briefing

Fu­eled by Covid prospects, Chi­nese vac­cine de­vel­op­er scores $230M to up­scale the whole pipeline

5 years ago
Financing

Covid-19 roundup: Pfiz­er, Mod­er­na say Biden's goal of hav­ing 600M dos­es by Ju­ly is with­in sight; EMA to con­sid­er ...

5 years ago
Coronavirus

Am­gen lines up ex­pan­sion to Ote­zla's $13B fran­chise; Chi­na OKs 'break­through' use of PD-1

5 years ago
News Briefing

De­spite red flag from FDA, con­tro­ver­sial ALS cell ther­a­py de­vel­op­er says it may still march ahead any­way

5 years ago
FDA+

Oton­o­my's res­ur­rect­ed ear drug is now dead again — and in­vestors aren't hang­ing around

5 years ago
R&D

A year af­ter tri­al fail­ure, As­traZeneca with­draws Imfinz­i's maid­en in­di­ca­tion in blad­der can­cer — but ex­ecs look to ...

5 years ago
Pharma

A gene ther­a­py leader stum­bles, Medicx­i's splashy 10-in-1 start­up play, a rad­i­cal HIV cure gets its shot​, and ...

5 years ago
Weekly

Covid-19 roundup: Pfiz­er/BioN­Tech say vac­cines can be stored short term at nor­mal freez­er temps; Fau­ci warns of ...

5 years ago
Coronavirus

Covid-19 roundup: South African vari­ant trips up Pfiz­er/BioN­Tech, Mod­er­na vac­cines while EU seeks an­ti-vari­ant ...

5 years ago
Coronavirus

VC style re­turns on 'un­sexy' pub­lic health bets? Gates-backed Ad­ju­vant Cap­i­tal gath­ers $300M to mend a 'fail­ure of ...

5 years ago
Financing

Mov­ing up the lines, As­traZeneca stakes an­oth­er PhI­II win for Lyn­parza as ad­ju­vant breast can­cer ther­a­py

5 years ago
R&D

Nek­tar, stung by new in­vestor law­suit over IL-2 drug, se­cures $150M for Keytru­da com­bo piv­otal tri­al

5 years ago
Deals

No­var­tis part­ners with the Gates Foun­da­tion on one of the Holy Grails in gene ther­a­py: a sim­ple, in vi­vo ap­proach to ...

5 years ago
Deals

'I’m not try­ing to re­build an ego': Neil Wood­ford ap­peals to pro­fes­sion­als for his come­back biotech fund

5 years ago
People
Financing

In a rare le­gal de­feat, Bris­tol My­ers Squibb and Sanofi fined $834M for 'de­cep­tive mar­ket­ing' on best-sell­ing blood ...

5 years ago
Pharma

Covid-19 roundup: Fau­ci says first graders could have ac­cess to vac­cine by Sep­tem­ber — re­port; EMA be­gins rolling ...

5 years ago
Coronavirus

Am­gen los­es ap­peal in patent suit against Sanofi/Re­gen­eron’s Pralu­ent. It’s a bum­mer for Bris­tol My­ers Squibb and ...

5 years ago
Pharma
First page Previous page 55565758596061 Next page Last page
A service from the Financial Times